Papers
1
Total Citations
129
H-Index
1
About
Dr. Changsen Lin is a pioneering researcher in synthetic biology and microbial-based cancer therapeutics, with a particular focus on engineering probiotic bacteria as living drug delivery systems. His most cited work, "Bioengineered *Escherichia coli* Nissle 1917 for tumour‐targeting therapy" (2019, 129 citations), represents a landmark contribution to the field of bacterial vector therapy. In this study, Dr. Lin demonstrated how *E. coli* Nissle 1917 can be reprogrammed as microscopic "robotic factories" through top-down bioengineering approaches to produce and deliver anticancer agents directly to tumor sites. This innovative strategy offers a safer alternative to pathogenic bacterial strains like *Salmonella typhimurium*, which have dominated earlier research. By harnessing a well-characterized probiotic chassis, Dr. Lin's work has opened new avenues for developing targeted, minimally invasive cancer treatments. His research bridges fundamental synthetic biology with translational medicine, establishing a platform that could revolutionize how we approach tumor-targeting therapies. With growing citation impact, Dr. Lin continues to advance the frontier of bacterial engineering for biomedical applications.
Research Focus
Key Achievements
Top Papers
- 1Bioengineered <i>Escherichia coli</i> Nissle 1917 for tumour‐targeting therapy129 citations · 2019